TY - JOUR
T1 - Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors
AU - Sayegh, Nicolas
AU - Yirerong, Juliet
AU - Agarwal, Neeraj
AU - Addison, Daniel
AU - Fradley, Michael
AU - Cortes, Jorge
AU - Weintraub, Neal L.
AU - Sayed, Nazish
AU - Raval, Girindra
AU - Guha, Avirup
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/4
Y1 - 2023/4
N2 - Purpose of Review: To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types. Recent Findings: Despite an undeniable survival advantage of tyrosine kinase inhibitors (TKIs) in patients with hematologic or solid malignancies, the accompanying off-target cardiovascular adverse events can be life-threatening. In patients with B cell malignancies, the use of Bruton tyrosine kinase inhibitors has been associated with atrial and ventricular arrhythmias, as well as hypertension. Cardiovascular toxic profiles are heterogeneous among the several approved breakpoint cluster region (BCR)-ABL TKIS. Notably, imatinib might be cardioprotective. Vascular endothelial growth factor TKIs, constituting the central axis in the treatment of several solid tumors, including renal cell carcinoma and hepatocellular carcinoma, have strongly been associated with hypertension and arterial ischemic events. Epidermal growth factor TKIs as therapy for advanced non-small cell lung cancer (NSCLC) have been reported to be infrequently associated with heart failure and QT prolongation. Summary: While tyrosine kinase inhibitors have been demonstrated to increase overall survival across different types of cancers, special consideration should be given to cardiovascular toxicities. High-risk patients can be identified by undergoing a comprehensive workup at baseline.
AB - Purpose of Review: To provide a detailed overview of cardiovascular adverse events associated with the use of tyrosine kinase inhibitors across different tumor types. Recent Findings: Despite an undeniable survival advantage of tyrosine kinase inhibitors (TKIs) in patients with hematologic or solid malignancies, the accompanying off-target cardiovascular adverse events can be life-threatening. In patients with B cell malignancies, the use of Bruton tyrosine kinase inhibitors has been associated with atrial and ventricular arrhythmias, as well as hypertension. Cardiovascular toxic profiles are heterogeneous among the several approved breakpoint cluster region (BCR)-ABL TKIS. Notably, imatinib might be cardioprotective. Vascular endothelial growth factor TKIs, constituting the central axis in the treatment of several solid tumors, including renal cell carcinoma and hepatocellular carcinoma, have strongly been associated with hypertension and arterial ischemic events. Epidermal growth factor TKIs as therapy for advanced non-small cell lung cancer (NSCLC) have been reported to be infrequently associated with heart failure and QT prolongation. Summary: While tyrosine kinase inhibitors have been demonstrated to increase overall survival across different types of cancers, special consideration should be given to cardiovascular toxicities. High-risk patients can be identified by undergoing a comprehensive workup at baseline.
KW - BCR-ABL
KW - Bruton tyrosine kinase
KW - Cardiovascular toxicity
KW - Tyrosine kinase inhibitor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85148105897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148105897&partnerID=8YFLogxK
U2 - 10.1007/s11886-023-01845-2
DO - 10.1007/s11886-023-01845-2
M3 - Review article
C2 - 36795308
AN - SCOPUS:85148105897
SN - 1523-3782
VL - 25
SP - 269
EP - 280
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 4
ER -